Introduction: This study is the first comparative assessment, internationally, of perceptions of generic medicines between general practitioners (GPs) and pharmacists in at least the last decade.
Methodology: One-to-one semi-structured interviews were performed with 34 GPs and 44 community pharmacists in Ireland. Interviews were transcribed and qualitative analyses were performed using NVivo (version 9).
Results: GPs expressed more negative opinions than pharmacists. 94.1% of GPs and 88.6% of pharmacists reported receiving complaints from patients related to generics. 11.8% of GPs versus 2.3% of pharmacists believed generics do not work as well as originators. More than twice as many GPs (14.7%) as pharmacists (6.8%) expressed a preference for the originator medication. Participants believed that most negative experiences reported by patients (with generic medicines) were not actual but imagined/nocebo.
Discussion: Education of stakeholders is a requirement for increased usage of generics. Resources to facilitate healthcare professionals in educating patients are needed. GPs' opinions could negatively influence patient opinions; countering these opinions may prove important for successful influencing of patient perceptions.
Download full-text PDF |
Source |
---|---|
http://dx.doi.org/10.1016/j.healthpol.2014.03.007 | DOI Listing |
Sci Rep
December 2024
School of Pharmacy, College of Health Sciences, Addis Ababa University, Addis Ababa, Ethiopia.
Access to health care is a fundamental human right. However, nearly one-third of the global population have no access to it. This magnitude is even much worse in low- and middle-income countries.
View Article and Find Full Text PDFTher Innov Regul Sci
December 2024
University of Witwatersrand, 7 York road, Parktown, Johannesburg, 2017, South Africa.
Purpose: This study aimed to assess the current regulatory review process of the Zambia Medicines Regulatory Authority (ZAMRA) by identifying the key milestones and target timelines achieved for products approved from 2020 to 2023, as well as good review and quality decision-making practices implemented in the review process.
Methods: A standardised, validated questionnaire; Optimising Efficiencies in Regulatory Agencies (OpERA) and the OpERA Data Collection Template were completed by the author.
Results: Three review models are used by ZAMRA to review new active substances (NASs) and generic products: verification, for products prequalified by the World Health Organization or approved by a stringent regulatory authority (SRA); abridged, for well-established molecules or SRA-approved products; or full, for products not otherwise prequalified.
Stud Mycol
December 2024
Department of Plant Pathology and Microbiology, College of Bioresources and Agriculture, National Taiwan University, Taipei, Taiwan.
Species classified in () include multiple entomopathogenic fungi. Numerous changes have recently occurred in the nomenclature of cordycipitaceous fungi due to the single naming system proposed for pleomorphic fungi in 2011. Species of are widely applied as herbal medicines, especially in Asian cultures.
View Article and Find Full Text PDFRheumatology (Oxford)
December 2024
Division of Preventive Medicine, Department of Medicine, University of Alberta, Edmonton AB, Canada.
Objectives: To summarise and evaluate Cochrane reviews of pharmacological therapies for adults with fibromyalgia syndrome (FMS) pain.
Methods: Systematic search of Cochrane Database of Systematic Reviews to May 2024. Generic quality assessment used AMSTAR-2 criteria, validity checks of potentially critical factors in evaluation of analgesic efficacy, and assessment of susceptibility of results to publication bias.
Lancet Glob Health
January 2025
School of Pharmacy, Faculty of Medicine and Health, University of Sydney, Sydney, NSW, Australia.
Background: Medication shortages are a pressing concern throughout the world. To gain insight into this issue, WHO and Health Action International (HAI) have constructed a validated method to survey medicine prices, availability, and affordability in low-income and middle-income countries. This paper aims to present an updated analysis of medicine affordability, availability, and pricing across 54 countries using the WHO-HAI method, highlighting disparities between public and private sectors.
View Article and Find Full Text PDFEnter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!